HK1177458A1 - Substituted imidazopyridinyl aminopyridine compounds - Google Patents

Substituted imidazopyridinyl aminopyridine compounds

Info

Publication number
HK1177458A1
HK1177458A1 HK13104562.5A HK13104562A HK1177458A1 HK 1177458 A1 HK1177458 A1 HK 1177458A1 HK 13104562 A HK13104562 A HK 13104562A HK 1177458 A1 HK1177458 A1 HK 1177458A1
Authority
HK
Hong Kong
Prior art keywords
substituted imidazopyridinyl
aminopyridine compounds
aminopyridine
compounds
imidazopyridinyl
Prior art date
Application number
HK13104562.5A
Other languages
English (en)
Chinese (zh)
Inventor
Mark A Ashwell
Chris Brassard
Anton Filikov
Jason Hill
Steffi Koerner
Jean-Marc Lapierre
Yanbin Liu
Nivedita Namdev
Robert Nicewonger
Rocio Palma
Manish Tandon
David Vensel
Akihisa Matsuda
Shin Iimura
Yuko Yamamoto
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of HK1177458A1 publication Critical patent/HK1177458A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
HK13104562.5A 2009-12-30 2013-04-16 Substituted imidazopyridinyl aminopyridine compounds HK1177458A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29092309P 2009-12-30 2009-12-30
PCT/US2010/062440 WO2011082270A2 (fr) 2009-12-30 2010-12-29 Composés imidazopyridinyl-aminopyridine substitués

Publications (1)

Publication Number Publication Date
HK1177458A1 true HK1177458A1 (en) 2013-08-23

Family

ID=44227150

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13104562.5A HK1177458A1 (en) 2009-12-30 2013-04-16 Substituted imidazopyridinyl aminopyridine compounds

Country Status (19)

Country Link
US (1) US8501770B2 (fr)
EP (1) EP2519522B1 (fr)
JP (1) JP5774602B2 (fr)
KR (1) KR101689421B1 (fr)
CN (1) CN102781940B (fr)
AU (1) AU2010339533B2 (fr)
CA (1) CA2785536C (fr)
CO (1) CO6511271A2 (fr)
DK (1) DK2519522T3 (fr)
ES (1) ES2531109T3 (fr)
HK (1) HK1177458A1 (fr)
IL (1) IL220571A (fr)
MX (1) MX2012007367A (fr)
MY (1) MY157124A (fr)
NZ (1) NZ600801A (fr)
RU (1) RU2619463C2 (fr)
SG (1) SG181947A1 (fr)
TW (1) TWI585086B (fr)
WO (1) WO2011082270A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
AU2012272937B2 (en) * 2011-06-24 2016-09-29 Arqule, Inc Substituted imidazopyridinyl-aminopyridine compounds
WO2013078254A1 (fr) * 2011-11-22 2013-05-30 Array Biopharma Inc. Dérivés hétéroaryles bicycliques en tant qu'inhibiteurs de kinase
US20140004044A1 (en) * 2012-05-17 2014-01-02 The University Of Chicago Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
US9617215B2 (en) 2012-05-17 2017-04-11 The University Of Chicago Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
AU2014312756B2 (en) * 2013-08-29 2018-11-22 Kyoto Pharmaceutical Industries, Ltd. Novel aromatic compound and use thereof
GB201321741D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CA2938923A1 (fr) * 2014-03-24 2015-10-01 Arqule Inc. Procede de preparation de 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3 h-imidazo [4,5-b]pyridin-2-yl)pyridin -2-amine
CN106795153B (zh) * 2014-04-22 2020-03-20 艾科尔公司 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型
KR20170045748A (ko) 2014-09-05 2017-04-27 아르퀼 인코포레이티드 증식성 질병의 치료를 위한 조성물 및 방법
CN105315161B (zh) * 2015-06-05 2017-08-04 厦门医学院 一类PKB/Akt抑制剂的关键中间体的制备方法
WO2018013430A2 (fr) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Composés hétérocycliques pour le traitement d'une infection à arenavirus
EP3493818A4 (fr) * 2016-08-07 2020-04-29 The Wistar Institute Of Anatomy And Biology Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
MA50895A (fr) 2017-11-14 2021-05-12 Merck Sharp & Dohme Nouveaux composés biaryles substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
EP3709986B1 (fr) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Nouveaux composés biaryles substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
EA202190952A1 (ru) 2018-10-05 2021-12-22 Аннапурна Байо, Инк. Соединения и композиции для лечения патологических состояний, связанных с активностью рецептора apj
EP4003961A2 (fr) * 2019-07-25 2022-06-01 Curadev Pharma Pvt. Ltd. Inhibiteurs à petites molécules de l'acétyl-coenzyme a synthétase à chaîne courte 2 (acss2)
CR20220547A (es) * 2020-05-01 2022-12-15 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina inhibidores de cd73
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
MX2023003576A (es) * 2020-09-30 2023-04-04 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto como inhibidor de la akt cinasa.
WO2022068929A1 (fr) * 2020-09-30 2022-04-07 武汉人福创新药物研发中心有限公司 Composé de pyrimidinedione et son utilisation
CN117769554A (zh) 2021-05-28 2024-03-26 大鹏药品工业株式会社 Kras突变蛋白的小分子抑制剂
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023168291A1 (fr) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Modificateurs covalents de akt1 et leurs utilisations
WO2024064026A1 (fr) * 2022-09-19 2024-03-28 Alterome Therapeutics, Inc. Modulateurs d'akt1
WO2024073371A1 (fr) * 2022-09-26 2024-04-04 Alterome Therapeutics, Inc. Modulateurs d'akt1
WO2024102621A1 (fr) * 2022-11-09 2024-05-16 Alterome Therapeutics, Inc. Modulateurs de akt1
WO2024107565A1 (fr) * 2022-11-14 2024-05-23 Alterome Therapeutics, Inc. Modulateurs de akt1

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3722992A1 (de) 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2002859C (fr) 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Methode de traitement d'affections epitheliales
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0800391A1 (fr) 1994-12-28 1997-10-15 Janssen Pharmaceutica N.V. Benzimidazoles utilises comme inhibiteurs du metabolisme du calcitriol
WO1999057103A1 (fr) 1998-04-30 1999-11-11 Nippon Chemiphar Co., Ltd. Derive d'imidazole condense et agent therapeutique permettant de traiter une maladie du foie
JP2000344780A (ja) 1998-09-24 2000-12-12 Fuji Photo Film Co Ltd 新規ベンゾピラン化合物、発光素子材料及びそれを使用した発光素子
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2001083481A1 (fr) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazopyridine
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
CN100522166C (zh) 2002-04-18 2009-08-05 先灵公司 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
EP1658289B1 (fr) * 2003-08-21 2009-03-18 OSI Pharmaceuticals, Inc. Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
CA2669736C (fr) 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Composes heterocycliques utiles comme modulateurs des tyrosine kinases
CA2634235A1 (fr) * 2005-12-21 2007-07-05 Schering Corporation Combinaison d'un antagoniste/agoniste inverse de h3 et d'un moderateur de l'appetit
MX2008012096A (es) * 2006-03-22 2008-12-17 Vertex Pharma Inhibidores de proteina cinasa c-met para el tratamiento de trastornos proliferativos.
CN100398540C (zh) 2006-04-03 2008-07-02 大连理工大学 芳杂环基咪唑并萘酰亚胺类化合物及其应用
CN101490037B (zh) 2006-07-11 2013-06-12 大熊制药株式会社 联芳基苯并咪唑衍生物以及包含该衍生物的药物组合物
WO2008108958A2 (fr) 2007-03-02 2008-09-12 Schering Corporation Dérivés de benzimidazole et leurs procédés d'utilisation
CA2691857A1 (fr) 2007-06-26 2008-12-31 Jorge Alonso Synthese regioselective catalysee par le cuivre de benzimidazoles et d'azabenzimidazoles
TW200932872A (en) 2007-10-17 2009-08-01 Cheil Ind Inc Novel compound for organic photoelectric device and organic photoelectric device including the same
KR20090007347U (ko) 2008-01-16 2009-07-21 춘-치 왕 가속 페달 포지션 센서를 구비한 자동차용 연료 공급 기구

Also Published As

Publication number Publication date
AU2010339533B2 (en) 2015-05-07
SG181947A1 (en) 2012-07-30
NZ600801A (en) 2013-09-27
WO2011082270A2 (fr) 2011-07-07
AU2010339533A1 (en) 2012-07-12
TWI585086B (zh) 2017-06-01
KR101689421B1 (ko) 2016-12-23
TW201132640A (en) 2011-10-01
JP5774602B2 (ja) 2015-09-09
RU2619463C2 (ru) 2017-05-16
IL220571A (en) 2015-03-31
US8501770B2 (en) 2013-08-06
WO2011082270A3 (fr) 2011-11-17
MX2012007367A (es) 2013-04-03
EP2519522A2 (fr) 2012-11-07
JP2013516419A (ja) 2013-05-13
CN102781940A (zh) 2012-11-14
DK2519522T3 (en) 2014-12-08
CO6511271A2 (es) 2012-08-31
US20110172203A1 (en) 2011-07-14
MY157124A (en) 2016-05-13
KR20120120271A (ko) 2012-11-01
CA2785536A1 (fr) 2011-07-07
CA2785536C (fr) 2018-02-27
ES2531109T3 (es) 2015-03-10
RU2012132444A (ru) 2014-02-10
EP2519522A4 (fr) 2013-03-13
EP2519522B1 (fr) 2014-09-24
CN102781940B (zh) 2016-09-07

Similar Documents

Publication Publication Date Title
HK1177458A1 (en) Substituted imidazopyridinyl aminopyridine compounds
IL235745A (en) Annotated 2-Aminopyridine
HK1196371A1 (zh) 被取代的咪唑並吡啶基-氨基吡啶化合物
ZA201201125B (en) Pyridin-4-yl derivatives
ZA201107772B (en) Substituted spiro-amide compounds
EP2519525A4 (fr) Composés de pyrroloaminopyrimidine substitués
GB0907425D0 (en) Compounds
EP2393493A4 (fr) Composés
EP2491025A4 (fr) Composés d'aza-azulène
GB0907515D0 (en) Compounds
HK1176606A1 (en) 2-pyridone compounds 2-
HK1169656A1 (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines n--1-(4-)-1h--3-
GB0905641D0 (en) Compounds
ZA201205726B (en) Substituted naphthalenyl-pyrimidine compounds
GB0918922D0 (en) Aminopyridine derivatives
EP2520570A4 (fr) Composé d'aminopyridine
EP2502909A4 (fr) Dérivé d'aminopyridine
AP2909A (en) Pyrazinoisoquinoline Compounds
EP2444401A4 (fr) Nouveau composé imidazopyridine
EP2443115A4 (fr) Composés
GB0919816D0 (en) Heterocyclic compounds
GB0919817D0 (en) Heterocyclic compounds
GB0902259D0 (en) Compounds
GB0906854D0 (en) Compounds
GB0902391D0 (en) Compounds